Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?

Key Takeaways Keytruda drove over half of Merck's pharma revenues in the first nine months of 2025.Keytruda sales rose 8% year over year in the third quarter but were weaker than expected.FDA nod to Keytruda Qlex extends patent protection beyond 2028 and aids potential long-term growth.Merck’s (MRK) strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical revenues.Keytruda, approved ...